Therefore, the expression of this protein could be considered a good predictive biomarker of the antitumoral effectiveness of HSP90 inhibitors, regardless of the molecular subtype of lung adenocarcinoma. The gene discussed is HSP90AB1; the disease is lung adenocarcinoma.